Verrica Pharmaceuticals Inc. VRCA Income Statement

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17
Operating expenses:
Research and development
15,841	15,436	16,381	16,799	16,386	12,826	9,027	6,680	4,142	3,730	0	0	0
General and administrative
16,093	14,644	13,897	13,268	11,630	9,052	6,097	3,470	1,633	727	0	0	0
Total operating expenses
31,934	30,080	30,278	30,067	28,016	21,878	15,124	10,150	5,775	4,457	0	0	0
Loss from operations
-31,934	-30,080	-30,278	-30,067	-28,016	-21,878	-15,124	-10,150	-5,775	-4,457	0	0	0
Other income (expense):
Interest income
1,608	1,877	2,133	2,107	1,737	1,231	0	0	0	-	-	-	-
Interest expense
0	-	-	-	-	-	-	-	-	-	-	-	-
Other expense
-	-	-	0	-	-	0	-	-	-	-	-	-
Interest expense - related party
-	-	-	-	-	-	-	-	-	-	0	-	-
Total other income
1,384	1,873	2,130	2,103	1,736	1,230	619	192	0	0	0	-	-
Net loss
-30,550	-28,207	-28,148	-27,964	-26,280	-20,648	-14,505	-9,958	-5,736	-4,459	0	0	0
Net loss per share, basic and diluted
-0.39	-0.31	-0.24	-0.28	-0.30	-0.30	-0.24	-0.92	-0.65	-0.50	-0.48	-0.38	-0.20
Weighted average common shares outstanding, basic and diluted
24,964	24,922	24,893	24,875	24,857	24,847	24,847	5,751	2,850	2,850	2,850	2,850	2,849
Net loss
-30,550	-28,207	-28,148	-27,964	-26,280	-20,648	-14,505	-9,958	-5,736	-4,459	0	0	0
Other comprehensive gain:
Unrealized gain on marketable securities
-	37	37	0	0	-	0	-	-	-	-	-	-
Comprehensive loss
-30,541	-28,170	-28,114	-27,926	-26,269	-20,665	0	0	0	-	0	-	-